Key result
In a rat model of monocrotaline-induced PAH, RP5063 improved pulmonary vascular pathology, hemodynamics, right ventricular hypertrophy, and systemic oxygen saturation.
Why the study?
Does RP5063 improve pulmonary hemodynamics and vascular pathology in a rat model of monocrotaline-induced pulmonary arterial hypertension?
Population
Rat model of monocrotaline-induced pulmonary arterial hypertension induced by a single 60mg/kg dose of MCT
Comparison
RP5063 administered via oral gavage twice-daily… vs Vehicle or sildenafil administered via oral…
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Provides preclinical proof-of-concept for 5-HT receptor modulation in pulmonary arterial.
Does RP5063 improve pulmonary hemodynamics and vascular pathology in a rat model of monocrotaline-induced pulmonary arterial hypertension?
RP5063, a novel 5-HT receptor modulator, demonstrates beneficial effects on pulmonary hemodynamics, right ventricular hypertrophy, and inflammation in a preclinical rat model of pulmonary arterial hypertension.
Bhat et al. (2017) studied Monocrotaline-induced pulmonary arterial hypertension. RP5063 vs. Vehicle or sildenafil (50mg/kg b.i.d.) was evaluated on Pulmonary vascular pathology, hemodynamics, right ventricular pressure and hypertrophy, systemic oxygen saturation. In a rat model of monocrotaline-induced PAH, RP5063 improved pulmonary vascular pathology, hemodynamics, right ventricular hypertrophy, and systemic oxygen saturation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: